Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleResearch Article

Down-regulation of Wnt Antagonist, SFRP1 in Colorectal Tumorigenesis

Zhi Xin, Leina Sun, Zhongli Zhan, Baocun Sun and Yi Yang
Chinese Journal of Clinical Oncology February 2008, 5 (1) 35-39; DOI: https://doi.org/10.1007/s11805-008-0035-1
Zhi Xin
1Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leina Sun
1Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhongli Zhan
1Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xinzhig{at}163.com
Baocun Sun
1Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Yang
1Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
3Core Laboratory, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

OBJECTIVE To assess the functional change of SFRP1 (secreted frizzled-related protein1), in colorectal tumorigenesis.

METHODS Immunohistochemical investigation and the semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) were used to assess the expression of SFRP1, β-catenin (β-cat) and E-caderin (E-cad) in matched samples of normal colorectal mucosa, adenomas and cancers.

RESULTS SFRP1 mRNA expression was down-regulated in the neoplasms, and abnormal expressions of β-cat and E-cad were found in colorectal adenomas and colorectal cancers.

CONCLUSION Down-regulation of SFRP1 observed is consistent with its acting as a tumor suppressor gene in colorectal tumorigenesis.

KEYWORDS:

keywords

  • SFRP1
  • colorectal tumorigenesis
  • immunohistochemistry
  • reverse transeriptase-polymerase chain reaction

Introduction

A family of secrected frizzled related proteins (SFRPS) have been recently described, which are genes of considerable interest in colorectal tumorigenesis. But there have been few systematic analyses of the expression of these genes in normal colorectal mucosa, colorectal adenomas and colorectal cancers, so little is known about their role in colorectal tumorigenesis. An association between SFRP1 and the development of colorectal cancer has not been found. In this study, we have examined the expression of the Wnt signaling antagonist SFRP1 for its possible role in colorectal tumorigenesis. To address this relationship, expression of SFRP1 and its correlative proteins, β-cat and E-cad in colorectal tumorigenesis, were investigated by immunohistochemical and the semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) in matchednormal colorectal mucosal tissues, colorectal adenomas and colorectal cancers.

Materials and Methods

Clinical material

Eighty colorectal adenomas, 85 colorectal cancers and their matched normal large bowel mucosal tissues were collected at the Tianjin Tumor Hospital. After excision of the tissue specimens, they were immediatedly frozen in liquid nitrogen and stored at -80°C for extraction of total RNA. Simultaniously tissues preserved for immunohistochemistry were fixed in buffered formalin, paraffin embedded, sectioned at 6 μm thickness, and mounted on glass slides. All tumor samples were reviewed by two independent pathologists, and classified according to WHO recommendations.

Methods

Semiquantitative RT-PCR

Total RNA was extracted using the TRIzol reagent (Helena Biosciences, Sunderland, United Kingdom) according to the manufacturer’s instructions. First-strand cDNA was synthesized from 500 ng of DNase-treated total RNA using 4 μl AMV buffer, 2 μl dNTP (10 mM each), 50 pmol oligo (dt) 18 primer, 20 U RNasin, 5 U AMV RT at 42°C for 60 min and 95°C for 5 min. In control reactions, AMV reverse transcriptase was omitted.

We amplified all of the genes (20 cycles to 35 cycles) to determine the appropriate conditions for obtaining semi-quantitative differences in their expression levels. A volume of 25 μl PCR reactions contained: Premix Taq 12.5 μl, cDNA 4 μl, forward and reverse primers 1μl each, and 1×PCR buffer, 6.5 μl. PCR amplification of the selected genes was performed with forward and reverse primers specific for each gene (Table 1) using the following cycle conditions: preheating at 94°C for 5 min; cycling at 94°C for 30 s, 55°C for 1 min, 72°C for 1 min; elongation at 72°C for 10 min. The PCR products were electrophoresed on 1.5% agarose gels containing ethidium bromide and visualized by UV-induced fluorescence. We also carried out PCR with β-actin (25 to 28 cycles) as internal control to ensure cDNA quality and loading accuracy. Primers were obtained from the AuGCT Biotechnology Synthesis Lab, Beijing.

View this table:
  • View inline
  • View popup
Table 1.

Primers used in RT-PCR.

Immunohistochemistry

The affinity-purified mouse monoclonal antibodies for β-cat (CAT-5H10) and E-cad (4A2C7) were purchased from Beijing Zhongshan Golden Bridge Biochnology Co., LTD. An EliVisionTMplus Polyr HRP (mouse/rabbit) IHC kit (KIT-9901) was purchased from Fujian Maxin-bio.

Six-micrometer tissue sections were deparaffinized in xylene, rehydrated in an ascending ethanol series (25%, 50%, 75%, 100%) and blocked by 3% H2O2 in methanol at room temprature for 10 min. The sections were heated in a microwave oven for 1 h to retrive the antigens and then incubated at 4°C overnight with the primary antibody. After washing the tissues with phosphate-buffered saline (PBS), they were incubated with biotinylated goat anti-mouse antibodies at room temprature for 30 min according to the manufacturer’ s instructions. Localization of the primary antibody was visualized with diaminobenzidine, which produced a brown stain, followed by hematoxylin counterstaining, dehydration in a descending methanol series (75%, 50%, 25%, 0%), and then examination by light microscopy.

For negative controls, serial sections were incubated with PBS instead of the primary antibody. We used hepatoma cells as a positive control for β-cat. According to Maruyama et al[1], brown stained cells are positive, including staining of the cell membranes, cytoplasm and nucleus. Expression of β-cat is mainly found on the cell membranes. Normal expression is defined as >70% positive cellular membrane, otherwise it is designated as membrane “expression deletion”. Positive expression of >10% in the cell nucleus is defined as “ectopic expression”. Both membrane “expression deletion” and “ectopic expression” are considered to be abnormal expression.

For E-cad expression assessment, staining of the cell membrane and/or cell nucleus was considered as positive expression. Based on a double blind method, we counted 100 cells in five areas under the light microscope (400×); and calculated the average positive ratio; ≥30% positive ratio marked normal expression, <30% marked abnormal expression.

Statistical analysis

Semiquantitative RT-PCR results were expressed as the mean±SD. Two sample comparisons were analyzed by the Student’s paired t test and 3 samples were analyzed by the χ2 test. ANOVA was performed to determine whether there was a significant difference between sample values within an experiment. To more clearly determine where those differences occurred, the Spearman rank correlation test and t test confirmed the significance of the differences. Using SPSS11.5 software, P values of 0.05 were considered as significant.

Results

Semiquantitative RT-PCR

Compared to the control groups, the expression of the SFRP1 gene in colorectal adenomas and colorectal cancers were down-regulated to values which were statistically different. Furthermore, the expression of SFRP1 in colorectal adenomas was lower than that found in colorectal cancers (P<0.05 Tables 2~4, Fig.1).

View this table:
  • View inline
  • View popup
Table 2.

SFRP1 mRNA in colorectal adenomas and their control group (Embedded Image).

View this table:
  • View inline
  • View popup
Table 3.

SFRP1 mRNA in colorectal cancers and their control group (Embedded Image).

View this table:
  • View inline
  • View popup
Table 4.

SFRP1 in colorectal adenomas, colorectal cancers and their control group (Embedded Image).

SFRP1 in colorectal adenomas, colorectal cancer and their control groups. 1, Controls; 2, Colorectal adenomas; 3, Colorectal cancer; 4, Marker.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.1.

SFRP1 in colorectal adenomas, colorectal cancer and their control groups. 1, Controls; 2, Colorectal adenomas; 3, Colorectal cancer; 4, Marker.

adenomas and colorectal cancers (Figs.6~7). We found

β-cat in normal colorectal mucosa
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.2.

β-cat in normal colorectal mucosa

β-cat in colorectal adenoma.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.3.

β-cat in colorectal adenoma.

β-cat in colorectal cancer.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.4.

β-cat in colorectal cancer.

E-cad in normal colorectal mucosa.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.5.

E-cad in normal colorectal mucosa.

E-cad in colorectal adenoma.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.6.

E-cad in colorectal adenoma.

E-cad in colorectal cancer.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.7.

E-cad in colorectal cancer.

Immunohistochemistry

A study of the β-cat and E-cad proteins in different colorectal tissues showed that expression of β-cat and E-cad was displayed on the epithelial cell membrane of normal colorectal mucosa (Figs.2 and 5), but they were expressed less to different degrees in colorectal that β-cat showed ectopic expression in the cytoplasm and cell nucleus (Figs.3~4), however its level of expression was lower in colorectal adenomas compared to colorectal cancers (87.5%, 100%, respectively, P<0.05). The depletion rates of β-cat and E-cad in colorectal adenomas (37.5% and 37.5% respectively) were lower than in colorectal cancers (58.8%, 76.4% respectively, P<0.05 Table 5). Table 6 shows that there was a direct association among the expression of β-cat and E-cad and down-regulation of SFRP1 in colorectal neoplasms.

View this table:
  • View inline
  • View popup
Table 5.

β-cat, E-cad expression in different colorectal tissues (%).

View this table:
  • View inline
  • View popup
Table 6.

Down-regulation of SFRP1 and β-cat, E-cad in colorectal neoplasms.

Discussion

Our studies indicate that down-regulation of SFRP1 is a frequent event in colorectal neoplasms. Other studies have previously demonstrated reduced transcription of SFRP1 in breast cancer[2-4], cervical cancer[5], pulmonary carcinosis[6], ovarian cancer, renal carcinoma[7] and gastric cancer[8], indicating that SFRP1 plays a role in many solid tumors.

Secreted frizzled-related proteins (SFRPs) have been found as competitive inhibitors of Wnt signaling by competing with membrane-bound frizzled proteins for Wnt binding[9,10]. Some studies have shown that the colorectal cancer cells died when SFRP1 was transducted into them where SFRP1 was down-regulated[11]. In our study, SFRP1 mRNA was down-regulated in colorectal neoplasms and its down-regulation increased from normal mucosa to adenomas to cancers, suggesting that SFRP1 acts as a tumor suppressor gene in colorectal carcinogenesis and that its down-regulation may initiate and/or promote colorectal cancer formation. Above all, SFRP1 may influence colorectal tumorigenesis at an early stage, and may promote progression of neoplasia to cancers.

The β-cat/E-cad complex mediates adherence of homoeotypic cells, and plays a significant role in maintaining normal cell polarity and integrity. The complex is a key factor that influences tumor cell infiltration and metastasis, when adherence between tumour cells is lost[12]. We found that in the tumors, β-cat and E-cad expression was depleted, and that β-cat was frequently ectopic in colorectal adenomas. With down-regulation of SFRP1, the ectopic expression of β-cat and E-cad increased from colorectal adenomas to colorectal cancer. Because of SFRP1’s down-regulation, Wnt signaling is consistent or its elements are mutated, which results in β-cat dephosphorylation and exceptional congestion in the cytoplasm. Therefore, the β-cat/E-cad complex can not form in the cell membranes, leading to its loss of activity in the cell membrane and initiation of tumor growth. Our research found that the depletion rates of β-cat and E-cad in the cell membranes of colorectal cancers (58.8%, 76.4%, respectively) were greater than in colorectal adenomas (37.5%, 37.5%, respectively), thus confirming our presumptions relating to these proteins.

In summary, our findings clearly demonstrate that SFRP1 expression is altered in colorectal carcinogenesis. Because SFRPS regulate a wide spectrum of Wnt activities and pathways, our results suggest that regulation of Wnt pathways plays a signifi cant role in colorectal carcinogenesis.

  • Received May 28, 2007.
  • Accepted November 15, 2007.
  • Copyright © 2008 by Tianjin Medical University Cancer Institute & Hospital and Springer

References

  1. ↵
    1. Maruyama K,
    2. Ochiai A,
    3. Akimoto S, et al.
    Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 2000; 59: 302-309.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wong SC,
    2. Lo SF,
    3. Lee KC, et al.
    Expression of frizzledrelated protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002; 196: 145-153.
    OpenUrlCrossRefPubMed
    1. Zhou Z,
    2. Wang J,
    3. Han X, et al.
    Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. Int J Cancer 1998; 78: 95-99.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ugolini F,
    2. Charafe-Jauffret E,
    3. Bardou VJ, et al.
    WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001;20: 5810-5817.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kawano Y,
    2. Kypta R
    , Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; l16: 2627-2634.
    OpenUrl
  5. ↵
    1. To KF,
    2. Chan MW,
    3. Leung WK, et al.
    Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci 2001; 70: 483-489.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Wang S,
    2. Krinks M,
    3. Lin K, et al.
    Frzb, a secreted protein expressed in Spemann organizer, binds and in-hibits Wnt-8. Cell 1997; 88: 757–766.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Suzuki H,
    2. Toyota M,
    3. Nojima M, et al.
    SFRP, a family of new colorectal tumor suppressor candidate genes. Nippon Rinsho 2005; 63: 707-719.
    OpenUrlPubMed
  8. ↵
    1. Ivanov DB,
    2. Philippova MP,
    3. Tkachuk VA.
    Structure and functions of classical cadherins. Biochemistry (Mosc) 2001; 66: 1174-1186.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Shih YL,
    2. Hsieh CB,
    3. Lai HC, et al.
    SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer 2007; 121: 1028-1035.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Yoon Y,
    2. Liang Z,
    3. Zhang X, et al.
    CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007: 67: 7518-7524.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Lee AY,
    2. He B,
    3. You L, et al.
    Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004; 23: 6672-6676.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 5 (1)
Chinese Journal of Clinical Oncology
Vol. 5, Issue 1
February 2008
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Down-regulation of Wnt Antagonist, SFRP1 in Colorectal Tumorigenesis
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Down-regulation of Wnt Antagonist, SFRP1 in Colorectal Tumorigenesis
Zhi Xin, Leina Sun, Zhongli Zhan, Baocun Sun, Yi Yang
Chinese Journal of Clinical Oncology Feb 2008, 5 (1) 35-39; DOI: 10.1007/s11805-008-0035-1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Down-regulation of Wnt Antagonist, SFRP1 in Colorectal Tumorigenesis
Zhi Xin, Leina Sun, Zhongli Zhan, Baocun Sun, Yi Yang
Chinese Journal of Clinical Oncology Feb 2008, 5 (1) 35-39; DOI: 10.1007/s11805-008-0035-1
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Monoclonal Antibodies in Cancer Therapy
  • From Bench to Bedside: Targeting Epigenetics for Cancer Therapy
  • Intussusception Induced by Transverse Colon Lipoma in a Young Male Patient—One Case Report
Show more Research Article

Similar Articles

Keywords

  • SFRP1
  • colorectal tumorigenesis
  • immunohistochemistry
  • reverse transeriptase-polymerase chain reaction

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire